Harrow (NASDAQ:HROW) CFO Acquires $104,650.00 in Stock

Harrow, Inc. (NASDAQ:HROW) CFO Andrew Boll purchased 3,500 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was bought at an average cost of $29.90 per share, with a total value of $104,650.00. Following the acquisition, the chief financial officer owned 814,679 shares of the company’s stock, valued at approximately $24,358,902.10. The trade was a 0.43% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Harrow Trading Up 3.5%

NASDAQ:HROW opened at $30.86 on Friday. The company has a market capitalization of $1.15 billion, a P/E ratio of -75.27 and a beta of 0.34. The company has a current ratio of 2.48, a quick ratio of 2.06 and a debt-to-equity ratio of 10.30. Harrow, Inc. has a 12 month low of $24.62 and a 12 month high of $54.85. The firm has a fifty day simple moving average of $36.67 and a 200-day simple moving average of $42.21.

Harrow (NASDAQ:HROW) last issued its earnings results on Monday, May 11th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.31). Harrow had a positive return on equity of 19.59% and a negative net margin of 5.57%.The firm had revenue of $44.20 million during the quarter, compared to analysts’ expectations of $52.43 million. During the same quarter last year, the business earned ($0.38) EPS. On average, equities research analysts anticipate that Harrow, Inc. will post 0.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on HROW. HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of Harrow in a report on Thursday, March 19th. B. Riley Financial reiterated a “buy” rating and issued a $65.00 price target (down from $74.00) on shares of Harrow in a report on Tuesday, April 7th. Nomura lowered shares of Harrow to a “neutral” rating in a research report on Wednesday, March 18th. Cantor Fitzgerald decreased their price objective on shares of Harrow from $91.00 to $88.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, BTIG Research reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Harrow in a report on Tuesday. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $69.43.

Hedge Funds Weigh In On Harrow

Several institutional investors and hedge funds have recently modified their holdings of HROW. Sei Investments Co. grew its holdings in Harrow by 119.5% during the first quarter. Sei Investments Co. now owns 38,032 shares of the company’s stock worth $1,341,000 after acquiring an additional 20,706 shares during the period. Militia Capital Management LLC acquired a new position in Harrow in the first quarter valued at approximately $829,000. First Trust Advisors LP boosted its position in Harrow by 1.2% in the 1st quarter. First Trust Advisors LP now owns 154,096 shares of the company’s stock worth $5,433,000 after purchasing an additional 1,865 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Harrow by 56.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 579,520 shares of the company’s stock worth $20,428,000 after purchasing an additional 208,972 shares during the period. Finally, KBC Group NV acquired a new stake in shares of Harrow during the 1st quarter worth approximately $31,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.